Trial Profile

Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids, and Neuroinflammation in HIV

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary) ; Tetrahydrocannabinol (Primary)
Indications Neurogenic inflammation
Focus Biomarker; Therapeutic Use
Acronyms CAMI

Most Recent Events

17 Feb 2025 Planned End Date changed from 31 Jul 2027 to 31 Oct 2027.
17 Feb 2025 Planned primary completion date changed from 31 Jul 2027 to 31 Oct 2027.
14 Nov 2024 Planned number of patients changed from 100 to 90.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com